RPL17 and neoplasm: Moreover, ALRN-6924 synergizes with anti-PD-1 and anti-PD-L1 to induce anti-tumor immunity resulting in an increased number of mice achieving complete regressions (CR), in both p53 wild-type and mutant tumors, compared to single agents.